RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sumitomo Pharma Co Stock

Sumitomo Pharma Co EBIT 2024

Sumitomo Pharma Co EBIT

-173.75 B JPY

Ticker

4506.T

ISIN

JP3495000006

WKN

858257

In 2024, Sumitomo Pharma Co's EBIT was -173.75 B JPY, a 220.91% increase from the -54.14 B JPY EBIT recorded in the previous year.

The Sumitomo Pharma Co EBIT history

YEAREBIT (undefined JPY)
2027e10.1
2026e27.27
2025e-2.02
2024-173.75
2023-54.14
202259.98
202190.02
2020118.12
201964.7
201893.71
201750.06
201636.93
201523.28
201442.14
201325.04
201220.4
201130.95
201035.63
200931.17
200837.74
200744.67
200628.26
20059.5

Sumitomo Pharma Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sumitomo Pharma Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sumitomo Pharma Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sumitomo Pharma Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sumitomo Pharma Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sumitomo Pharma Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sumitomo Pharma Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sumitomo Pharma Co’s growth potential.

Sumitomo Pharma Co Revenue, EBIT and net profit per share

DateSumitomo Pharma Co RevenueSumitomo Pharma Co EBITSumitomo Pharma Co Net Income
2027e365.34 B undefined10.1 B undefined2.36 B undefined
2026e361.96 B undefined27.27 B undefined7.22 B undefined
2025e346.77 B undefined-2.02 B undefined-10.17 B undefined
2024314.56 B undefined-173.75 B undefined-314.97 B undefined
2023555.54 B undefined-54.14 B undefined-74.51 B undefined
2022560.04 B undefined59.98 B undefined56.41 B undefined
2021515.95 B undefined90.02 B undefined56.22 B undefined
2020482.73 B undefined118.12 B undefined40.75 B undefined
2019459.27 B undefined64.7 B undefined48.63 B undefined
2018466.84 B undefined93.71 B undefined53.45 B undefined
2017408.36 B undefined50.06 B undefined31.32 B undefined
2016403.21 B undefined36.93 B undefined24.7 B undefined
2015371.37 B undefined23.28 B undefined15.45 B undefined
2014387.69 B undefined42.14 B undefined20.06 B undefined
2013347.72 B undefined25.04 B undefined10.04 B undefined
2012350.4 B undefined20.4 B undefined8.63 B undefined
2011379.51 B undefined30.95 B undefined16.8 B undefined
2010296.26 B undefined35.63 B undefined20.96 B undefined
2009264.04 B undefined31.17 B undefined19.99 B undefined
2008263.99 B undefined37.74 B undefined25.59 B undefined
2007261.21 B undefined44.67 B undefined22.61 B undefined
2006245.78 B undefined28.26 B undefined15.33 B undefined
2005173.9 B undefined9.5 B undefined6.9 B undefined

Sumitomo Pharma Co stock margins

The Sumitomo Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sumitomo Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sumitomo Pharma Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sumitomo Pharma Co's sales revenue. A higher gross margin percentage indicates that the Sumitomo Pharma Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sumitomo Pharma Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sumitomo Pharma Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sumitomo Pharma Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sumitomo Pharma Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sumitomo Pharma Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sumitomo Pharma Co Margin History

Sumitomo Pharma Co Gross marginSumitomo Pharma Co Profit marginSumitomo Pharma Co EBIT marginSumitomo Pharma Co Profit margin
2027e59.78 %2.76 %0.65 %
2026e59.78 %7.53 %1.99 %
2025e59.78 %-0.58 %-2.93 %
202459.78 %-55.24 %-100.13 %
202367.87 %-9.75 %-13.41 %
202271.95 %10.71 %10.07 %
202173.32 %17.45 %10.9 %
202073.27 %24.47 %8.44 %
201975.28 %14.09 %10.59 %
201875.93 %20.07 %11.45 %
201776.83 %12.26 %7.67 %
201674.09 %9.16 %6.13 %
201572.74 %6.27 %4.16 %
201473.14 %10.87 %5.17 %
201370.75 %7.2 %2.89 %
201271.79 %5.82 %2.46 %
201171 %8.16 %4.43 %
201062.1 %12.03 %7.07 %
200960.7 %11.8 %7.57 %
200861.57 %14.3 %9.69 %
200761.63 %17.1 %8.65 %
200646.67 %11.5 %6.24 %
200535.6 %5.46 %3.96 %

Sumitomo Pharma Co Aktienanalyse

What does Sumitomo Pharma Co do?

Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Sumitomo Pharma Co's EBIT

Sumitomo Pharma Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Sumitomo Pharma Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Sumitomo Pharma Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Sumitomo Pharma Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Sumitomo Pharma Co stock

How much did Sumitomo Pharma Co achieve in EBIT for the current year?

In the current year, Sumitomo Pharma Co has achieved an EBIT of -173.75 B JPY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Sumitomo Pharma Co.

How has the EBIT of Sumitomo Pharma Co developed in recent years?

The EBIT of Sumitomo Pharma Co has increased by 220.912% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Sumitomo Pharma Co?

The EBIT of Sumitomo Pharma Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Sumitomo Pharma Co pay?

Over the past 12 months, Sumitomo Pharma Co paid a dividend of 14 JPY . This corresponds to a dividend yield of about 2.49 %. For the coming 12 months, Sumitomo Pharma Co is expected to pay a dividend of -5.34 JPY.

What is the dividend yield of Sumitomo Pharma Co?

The current dividend yield of Sumitomo Pharma Co is 2.49 %.

When does Sumitomo Pharma Co pay dividends?

Sumitomo Pharma Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Sumitomo Pharma Co?

Sumitomo Pharma Co paid dividends every year for the past 2 years.

What is the dividend of Sumitomo Pharma Co?

For the upcoming 12 months, dividends amounting to -5.34 JPY are expected. This corresponds to a dividend yield of -0.95 %.

In which sector is Sumitomo Pharma Co located?

Sumitomo Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sumitomo Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sumitomo Pharma Co from 6/1/2023 amounting to 7 JPY, you needed to have the stock in your portfolio before the ex-date on 3/30/2023.

When did Sumitomo Pharma Co pay the last dividend?

The last dividend was paid out on 6/1/2023.

What was the dividend of Sumitomo Pharma Co in the year 2023?

In the year 2023, Sumitomo Pharma Co distributed 28 JPY as dividends.

In which currency does Sumitomo Pharma Co pay out the dividend?

The dividends of Sumitomo Pharma Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sumitomo Pharma Co

Our stock analysis for Sumitomo Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sumitomo Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.